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Abstract Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-
CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development
by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant
melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in
phase III development for the melanoma and prostate cancer indications, and
phase II for lymphoma and non-small cell lung cancer in the US and other
areas of the world. This review discusses the key development milestones and
therapeutic trials on this drug to date.
1. Introduction
Bristol-Myers Squibb (BMS) is developing an
anti-CTLA-4 monoclonal antibody, ipilimumab,
as a treatment for malignant melanoma, prostate
cancer and non-small cell lung cancer. Ipilimu-
mab blocks the effects of the negative T-cell reg-
ulator CTLA-4, which may, in turn, augment
T-cell responses to tumor cells. Preclinical studies
have indicated that blocking CTLA-4 with an
antibody can lead to potent immune responses.
Ipilimumab is awaiting approval as second-line
therapy for metastatic melanoma in the EU. The
compound is also in phase III development as
first-line therapy for melanoma and prostate
cancer worldwide, and is in phase II development
for non-small cell lung cancer.
Ipilimumab was originated by the University
of California in the US. The compound was
subsequently licensed to Medarex, which was
later acquired by BMS.
Data from a survey of US and European on-
cologists in 2009 have indicated that ipilimumab
would earn a higher patient share in the US
(60%) than in Europe (40%) for treating stage IV
malignant melanoma.[1]
1.1 Company Agreements
In September 2009, Medarex became a wholly
owned subsidiary of BMS.[2]
In January 2005, Medarex and BMS entered
into a worldwide collaboration to develop and
commercialize ipilimumab and MDX 1379. BMS
and Medarex were to share profits and the costs
of developing the compounds in the US and
EU based on a pre-agreed percentage allocation.
BMS was to receive an exclusive licence to
territories outside the US and pay royalties to
Medarex. Medarex will receive an initial cash pay-
ment of $US50million and up to $US480million in
regulatory and sales-related milestone payments.[3]
In May 2003, Cell Genesys and Medarex en-
tered into a research and development collabo-
ration to evaluate combination therapy with Cell
Genesys’ GVAX prostate cancer vaccine and
ipilimumab. A phase I trial was completed for
this combination therapy and under terms of the
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agreement, both companies shared the cost of
the trial equally. However, Cell Genesys dis-
continued all clinical development activities in
June 2009 as part of its restructuring plan.[4]
In June 2002, Medarex entered into a joint
development and supply agreement with IDM
(later IDM Pharma). Under the agreement, ipi-
limumab and various Cell Drug combinations
were be investigated. The first combination to
undergo investigation was expected to be ipili-
mumab and IDD 1.
However, the development of IDD 1 was later
discontinued. Earlier, in December 1999, IDM
became Medarex’s first partner in a program
investigating the use of CTLA-4 blockade tech-
nology to increase the efficacy of cancer vaccines.
In August 1999, Medarex obtained an ex-
clusive sublicense from Gilead Sciences. The
sublicense gave Medarex access to the CTLA-4
blockade intellectual property rights owned by
the University of California, Berkeley (UC Ber-
keley), CA, USA, which held a number of patents
relating to blockade of CTLA-4. Gilead Sciences
had previously acquired a sublicensable licence
from UC Berkeley, through its merger with
NeXstar Pharmaceuticals. The sublicense al-
lowed Medarex to further develop fully human
antibodies that inhibit CTLA-4, including ipili-
mumab, which was created using Medarex’s
proprietary HuMAb-Mouse technology. Un-
der the terms of the sublicensing agreement,
Medarex also had an option to develop non-
antibody agents that block CTLA-4. Both Gilead
Sciences and UC Berkeley were to receive a roy-
alty split based on future product sales and UC
Berkeley was also to receive milestone payments.
1.2 Key Development Milestones
1.2.1 Malignant Melanoma (Second-Line Therapy)
BMS filed a MAA with the European Medi-
cines Agency in the first half of 2010, for ipili-
mumab as second-line therapy in patients with
metastatic melanoma. The company expects to
file a BLA submission with the US FDA for the
same indication in 2010.
Overall survival was significantly extended
in patients with previously treated metastatic
melanoma who received ipilimumab compared
with patients who received therapy with a gp100
peptide vaccine, thus meeting the primary end-
point of a phase III trial (NCT00094653; Study
020) of the agent. In this double-blind trial,
patients were randomized to receive ipilimumab
alone, ipilimumab in combination with a gp100
peptide vaccine, or the control therapy of gp100
alone. The study enrolled approximately 676
patients with unresectable stage III or IV meta-
static melanomawho had received prior therapies
and who were HLA-A2-positive, at sites in the
US, EU, Canada, Argentina, Brazil, Chile, South
Africa, Switzerland, and the UK. Fast track sta-
tus has been granted to this combination therapy
by the US FDA. The gp100 vaccine, also called
MDX 1379, consists of two gp100 melanoma
peptides that Medarex in-licensed from the US
NCI. The study was designed under the SPA
process.[5-9]
Medarex and BMS conducted a registrational
monotherapy program to evaluate ipilimumab
for the treatment of metastatic melanoma. The
program consisted of three phase III trials (008,
022, and 007) which enrolled a total of 487
patients with advanced stage III or stage IV
metastatic melanoma from centres across the US,
EU, South America, and Africa. Study 008 was
an open-label, single-arm trial evaluating overall
response rate in 155 patients who progressed on
or following standard treatment. Study 002 was a
randomized, double-blind trial that evaluated the
efficacy of three dose levels of ipilimumab in 216
patients who were previously treated, relapsed or
failed to respond to experimental treatment or
who were unable to tolerate currently approved
therapies. Finally, study 007 was a randomized,
double-blind, placebo-controlled trial in 116
patients, comparing the safety of ipilimumab,
with or without prophylactic oral budesonide.
The ipilimumab monotherapy program was re-
viewed under a SPA inMarch 2006. In December
2006, ipilimumab received fast track designation
from the FDA for use as a monotherapy in
previously treated patients with metastatic mela-
noma.[10] Top-line results from studies 008, 022,
and 007 have been announced. The results from
study 008 did not meet the primary endpoint,
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which was to rule out a best objective response
rate of less than 10%. However, the totality of
data from the registrational program included a
clear dose response effect observed in study 022
and best objective response rates across the three
studies as determined by independent radiology
review.[10,11]
BMS, in collaboration with the MDAnderson
Cancer Center, have initiated a phase II trial
evaluating the combination of ipilimumab
and temozolomide in metastatic melanoma
(NCT01119508). In the induction phase of the
trial, patients will receive open-label treatment
with intravenous ipilimumab 10mg/kg over
90 minutes on day 1, plus oral temozolomide
200mg/m2 on days 1–4; both drug regimens
will continue to be administered every 3 weeks
for four courses over 3 months. In the mainten-
ance phase of the study, ipilimumab treatment
will continue as above every 12 weeks, whilst
temozolomide will be administered on day 1–5,
and repeated every 4 weeks. Approximately 64
patients will be enrolled.
1.2.2 Malignant Melanoma (First-Line Therapy)
A phase III registrational trial (NCT00324155)
of ipilimumab in combination with chemothera-
py (dacarbazine) as a first-line treatment for
patients with unresectable stage III or IV meta-
static melanoma began in June 2006, and was
cleared to continue by a data monitoring com-
mittee in 2008. The trial is being conducted in the
US, Europe, Canada, Australia, Israel, South
Africa, and South America. The double-blind,
two-arm study has approximately 500 patients
with previously untreated stage III or IV meta-
static melanoma who have been randomized to
receive dacarbazine with or without ipilimumab
(10mg/kg). Treatments will be administered once
every 3 weeks for up to four doses and patients
who have no experienced disease progression at
week 24 will continue in a maintenance phase
where a single dose of ipilimumab will be ad-
ministered once every 12 weeks until disease
progression. The primary endpoint is overall
survival. The trial is expected to be completed in
late 2011. Fast-track status was granted for this
indication in the US.[12-15]
1.2.3 Non-Small Cell Lung Cancer
BMS has completed a double-blind, phase II
trial (NCT00527735, 041) of ipilimumab in patients
with previously untreated advanced non-small
cell lung cancer. Approximately 330 patients were
randomized to receive ipilimumab in combina-
tion with paclitaxel/carboplatin or paclitaxel/
carboplatin alone. The trial was conducted at
sites in the US, EU, Russia, and India. Positive
data were reported in May 2010. The study met
its primary endpoint (defined as significant im-
provement in immune-related progression-free
survival).[16] BMS intends to commence a phase
III study of ipilimumab for the treatment of non-
small cell lung cancer in 2010.[16]
1.2.4 Prostate Cancer
BMS is recruiting patients in a phase III clin-
ical trial (NCT00861614) to assess ipilimumab
in combination with radiotherapy, compared to
radiotherapy alone, in patients with castration-
resistant prostate cancer who have received prior
treatment with docetaxel. This trial is expected to
recruit approximately 800 patients and is taking
place in the US, Canada, Europe, Australia, and
Latin America. BMS plans to commence a second
phase III trial (NCT01057810) in August 2010
in patients with metastatic castration-resistant
prostate cancer. Approximately 600 patients will
be enrolled at sites in US, Canada, Europe,
Australia, India, and Latin America.
BMS has completed a phase I/II trial
(NCT00323882) of ipilimumab in patients with
metastatic hormone-refractory prostate cancer in
the US. The trial recruited 66 patients who had
not previously received chemotherapy or imm-
unotherapy. Four dose levels were investigated.
Interim results from a phase I trial of ipilimu-
mab in combination with Cell Genesys’ GVAX
vaccine in patients with metastatic hormone-
refractory prostate cancer were presented in June
2007. The multi-dose, dose-escalation trial was
conducted in the Netherlands and evaluated the
safety and efficacy of the combination therapy.
Additional results from this trial were released in
April 2008. This trial arose from a collaboration
entered into by Medarex and Cell Genesis in
2003.[17-19] However, in June 2009, Cell Genesys
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discontinued all clinical development activities
including the development of GVAX immuno-
therapy for prostate cancer.[4]
1.2.5 Other Cancers
In October 2009, BMS completed a phase I
study (NCT00362713) of ipilimumab as neo-
adjuvant therapy in patients with urothelial
cancer. Twelve patients were enrolled in the
US. The tolerability and anticancer immuno-
logical activity of ipilimumab monotherapy was
investigated.
Results from a phase I trial in patients with
various cancers including lymphomas (Hodgkin
and non-Hodgkin) and treated with ipilimumab
after relapse of their tumor following allogeneic
hematopoietic stem cell transplantation have
been presented. Results have also been presented
from a phase I/II trial with ipilimumab in patients
with relapsed or refractory follicular lympho-
ma.[20] Additional trials were planned. However,
no recent development has been reported.
Another phase I trial of the agent in combi-
nation with the GVAX vaccine was conducted
in patients with a range of tumors, including
metastatic melanoma, non-small cell lung cancer,
ovarian cancer, acute myeloid leukemia and
myelodysplastic syndromes.[21]
1.3 Patent Information
BMS owns a composition of matter patent
covering ipilimumab, which expires in the US in
2016. The company also has rights to method of
use patents owned by Medarex that expire in the
US in 2015. BMS has rights to a Medarex com-
position of matter patent that expires in 2020
(extended to 2022 by a patent term adjustment)
and also has pending Medarex patent applica-
tions covering composition of matter andmethod




Phase I : In a phase I trial in 17 patients with
lymphomas (Hodgkin, non-Hodgkin), myeloma,
Table I. Features and properties
Alternate names BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4
Originator University of California at Berkeley
Highest development phase Preregistration (EU)
Active development-indications Malignant melanoma, non-small cell lung cancer, prostate cancer, urogenital cancer
Class Monoclonal antibodies
Mechanism of action Cytotoxic T-lymphocyte antigen 4 inhibitors, immunostimulants, T-lymphocyte stimulants
Chemical name Immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human g1-chain), disulphide with human k-chain,
dimer
Molecular formula C6472 H9972 N1732 O2004 S40
CAS registry number 477202-00-9
Route of administration IV
Pharmacodynamics Inhibition of tumor growth in mice; eradication of primary and metastatic murine melanomas with anti-
CTLA-4+ sargramostim-producing vaccines; dose-dependent increase in T-cell activation and decreases
in serum prostate specific antigen levels in prostate cancer patients;
Immunogenicity Combination therapy with GVAX and ipilimumab enhances T-cell and dendritic cell activity; increases
T-cell activation with a concurrent reduction in naive T cells
ATC codes
WHO ATC code L01X-C (monoclonal antibodies), L03A (immunostimulants)
EphMRA ATC code L1X3 (antineoplastic monoclonal antibodies), L3A (immunostimulating agents excluding interferons)
Adverse events
Occasional Adrenal insufficiency, arthritis, colitis, dermatitis, diarrhea, fatigue, hepatitis, hypopituitarism,
laryngospasm, neutropenia, pancreatitis, skin eruptions, uveitis
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leukemia (chronic myeloid, chronic lymphocytic,
acute myeloid), renal, and breast cancers, who
were treated with ipilimumab (0.1–3.0mg/kg)
after relapse of their tumor following allogeneic
hematopoietic stem cell transplantation showed
that the drug was generally tolerable and without
dose-limiting toxicities or clinically important
graft-versus-host disease. Two possible immune-
related adverse events included one grade 2 (thy-
roid function test abnormalities without clinical
symptoms) and one grade 3 polyarthropathy.[20]
Preliminary results from an ongoing phase I/II
clinical trial in 12 patients with relapsed or
refractory follicular lymphoma showed that ipi-
limumab was generally tolerable. There were six
grade 3 adverse events, including diarrhea (4),
fatigue (1), and neutropenia (1).[20]
2.1.2 Melanoma
Phase III :Themost common side effects (SEs)
were immune-related in a phase III trial of ipili-
mumab, alone and in combination with a gp100
peptide vaccine, in patients with unresectable
stage III or IV metastatic melanoma who had
received prior therapies and who were HLA-A2-
positive. In this double-blind trial, patients were
randomized to receive ipilimumab plus gp100
(3mg/kg and 1mg/kg every 3 weeks for four
doses; n= 403), ipilimumab plus placebo (3mg/kg
every 3 weeks for four doses; n = 137) or gp100
plus placebo (n = 136). Grade 3/4 drug-related
adverse events (AEs) were observed in 17%, 23%
and 11% of the ipilimumab plus gp100, ipilimu-
mab and gp100 arms, respectively. Grade 3/4
immune-related AEs (irAEs) were observed in
10–15% of the ipilimumab treatment arms, and
3% in the gp100 alone arm. The irAEs were some-
times severe and life-threatening and most often
affected the gastrointestinal, skin, liver, or endo-
crine systems. A total of 14 drug-related deaths
(2.1%, 3.1%, and 1.5% of each of the respective
groups) occurred in the study, with seven (1.3%,
1.5%, and 0% of the respective groups) attributed
to an irAE. All irAEs were treated with the use of
supportive care and systemic steroids using estab-
lished protocol-specific treatment guidelines.[5,6]
Phase II : In data for three phase I studies (008,
022, and 007), the most common immune-related
adverse events were rash, diarrhea, and hepatitis.
Grade 3 and 4 immune-related adverse event
rates were approximately 20–28% and 0–12%,
respectively.[22]
Ipilimumab plus budesonide and ipilimumab
plus placebo in 115 patients were associated with
a similar incidence of diarrhea in patients with
malignant melanoma (33% and 35%, respective-
ly) in a phase II trial. Prophylactic budesonide
did not appear to have a clinically meaningful
effect on diarrhea. Most patients had at least one
immune-related adverse event. However, no
bowel perforations were reported and ipilimu-
mab was generally well tolerated. Adverse events
involving the CNS were reported in 5 of 16 pa-
tients, and considered drug-related in two (grade 2
headache and grade 1 dizziness). There was an
increase irAEs from 0.3 to 3 to 10mg/kg.[23-26]
In a phase II study of ipilimumab in combi-
nation with MDX 1379 at 3 or 1mg/kg/day,
grade 3/4 adverse events were observed in 31%
and 26%, respectively, of patients with metastatic
malignant melanoma. The most frequent events
were colitis and dermatitis. Grade 3/4 events were
reported in all patients with an extended com-
plete or partial response duration.[27]
Interim results from 12 months extended dos-
ing with ipilimumab (3.0mg/kg) and MDX 1379
in 25 patients with resected stage IIIc or stage IV
melanoma showed that the regimen was generally
well tolerated. Twelve patients experienced grade
II or III colitis, rash, or hypopituitarism (immune
breakthrough events).[28]
Phase I : In a phase I/II trial of metastatic
melanoma patients receiving ipilimumab in
combination with IL-2, five patients reported
grade 3/4 adverse events, including colitis, and
uveitis, which were consistent with the immune-
based mechanism of action, as well as pan-
creatitis, arthritis, and laryngospasm. All patients
recovered without sequelae.[29]
In a study in melanoma patients treated
with ipilimumab at 9mg/kg and presenting with
dermatitis, skin manifestations consisted of pru-
ritic, localized erythematous papules and thin
plaques. Histologically, CD4-predominant T-cell
infiltrates with rare dyskeratotic cells, mild to
moderate spongiosis, occasional exocytosis of
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Table II. History
Date Comment
1 July 2010 No development reported – phase II for Lymphoma in USA (IV)
9 June 2010 inThought Analysis for malignant melanoma updated
8 June 2010 Interim efficacy and adverse event data from a phase III trial in metastatic melanoma presented at the 46th Annual
Meeting of the American Society of Clinical Oncology (ASCO-2010)[5,6]
1 June 2010 Preregistration for malignant melanoma in EU (IV)
27 May 2010 Bristol-Myers Squibb initiates enrollment in a phase II trial for malignant melanoma in the US
25 May 2010 Safety and efficacy data from a phase II study in non-small cell lung cancer released by Bristol-Myers Squibb[16]
2 September 2009 Medarex has been acquired by Bristol-Myers Squibb
1 June 2009 Interim efficacy data from a pooled analysis of phase II trials in malignant melanoma presented at the 45th Annual
Meeting of the American Society of Clinical Oncology (ASCO-2009)[37]
31 May 2009 Phase III clinical trials in prostate cancer in Australia (IV)
31 May 2009 Phase III clinical trials in prostate cancer in Canada (IV)
31 May 2009 Phase III clinical trials in prostate cancer in Europe (IV)
31 May 2009 Phase III clinical trials in prostate cancer in Latin America (IV)
31 May 2009 Phase III clinical trials in prostate cancer in USA (IV)
16 September 2008 Efficacy and adverse events data from three phase II trials in malignant melanoma released by Bristol-Myers Squibb
and Medarex[22]
16 September 2008 Efficacy, adverse events, and immunogenicity data from a phase II trial in malignant melanoma presented at the 33rd
Congress of the European Society for Medical Oncology (ESMO-2008)[23-25,35,40,41]
1 July 2008 Phase II clinical trials in malignant melanoma and brain metastases in the US (IV)
3 June 2008 Efficacy and adverse events data from a phase II trial of ipilimumab plus budesonide in malignant melanoma
presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)[26]
3 June 2008 Interim adverse events data from a phase I trial in prostate cancer presented at the 44th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2008)[34]
2 June 2008 Efficacy data from phase III, phase II, and phase I/II trials in malignant melanoma presented at the 44th Annual
Meeting of the American Society of Clinical Oncology (ASCO-2008)[38,42-44]
25 April 2008 Phase II clinical trials in non-small cell lung cancer in the US (IV)
25 April 2008 Phase II clinical trials in non-small cell lung cancer in EU (IV)
16 April 2008 Interim efficacy data and pharmacodynamic data from phase I trials in prostate cancer presented at the 99th Annual
Meeting of the American Association for Cancer Research (AACR-2008)[17,36,49]
3 April 2008 Data Monitoring Committee recommends the phase III study of ipilimumab study 024 should continue[13]
1 October 2007 Phase I clinical trials in urogenital cancer in the US (IV)
11 June 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the
adverse events, cancer therapeutic trials, and cancer immunogenicity sections[19,45]
9 January 2007 Medarex completes enrollment in its single-arm, monotherapy phase III trial for metastatic melanoma
11 December 2006 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006)
added to the adverse events and cancer therapeutic trials sections[20]
7 December 2006 Ipilimumab receives fast-track status for use as a monotherapy in the second-line treatment of malignant melanoma
in the US
7 December 2006 Ipilimumab receives fast-track status for use in combination with dacarbazine as a first-line treatment for malignant
melanoma in the US
19 June 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been
added to the adverse events and cancer pharmacodynamics and therapeutic trials sections[28,31,33]
31 March 2006 Medarex has initiated enrollment in a registrational phase III trial of ipilimumab monotherapy for metastatic
melanoma worldwide
23 March 2006 Data presented at the Prostate Cancer Symposium 2006 (PCS-2006) have been added to the cancer
pharmacodynamics and adverse events sections[32]
Continued next page
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T cells and eosinophils in the dermis were observed.
Five patients also presented with an increase in
the peripheral blood eosinophil count. Ipilimu-
mab-treated patients who developed skin mani-
festations also tended to develop a more focal
cutaneous reaction with a predominance of
CD+4 T cells in the dermis.[30]
2.1.3 Non-Small Cell Lung Cancer
Phase II : In a double-blind, phase II trial (041)
in patients with previously untreated advanced
non-small cell lung cancer receiving treatment
with ipilimumab in combination with paclitaxel/
carboplatin, grade 3/4 adverse events were ob-
served in 58%, 52%, and 42% of patients in the
concurrent, phased and paclitaxel/carboplatin
alone groups, respectively. The incidences of
grade 3/4 irAEs were 20% and 15% for the con-
current and phased groups, respectively. These
events were treated with supportive care and
systemic steroids based on established protocol
treatment guidelines.[16]
2.1.4 Prostate Cancer
Phase II : Ipilimumab (either alone or in combi-
nation with docetaxel) was generally well tolerated
Table II. Contd
Date Comment
29 August 2005 A study has been added to the cancer therapeutic trials section[50]
22 July 2005 Data presented at the 66th Annual Meeting of the Society of Investigative Dermatology (SID-2005) have been added
to the adverse events section[30]
5 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have
been added to the adverse events and cancer therapeutic trials sections[27]
31 March 2005 Phase III clinical trials in breast cancer in the world (IV)
31 March 2005 Phase III clinical trials in malignant melanoma in the world (IV)
9 March 2005 Data from a media release have been added to the adverse events and cancer therapeutic trials sections[29]
10 November 2004 Ipilimumab has been licensed to Bristol-Myers Squibb worldwide excluding the US
7 October 2004 MDX 010 in combination with MDX 1379 has received fast track status for malignant melanoma in the US
29 September 2004 Phase III clinical trials in malignant melanoma in the US (IV)
13 September 2004 Phase I clinical trials in prostate cancer in the Netherlands in combination with GVAX (IV)
25 August 2004 Medarex has received US FDA agreement on its SPA for a phase III study of MDX 010 in melanoma
6 July 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been
added to the cancer therapeutic trials section[21]
14 June 2004 Ipilimumab has received Orphan Drug Status for malignant melanoma in the US
23 April 2004 Phase I clinical trials in solid tumors and hematological malignancies in combination with GVAX in the US (IV)
23 April 2004 Phase II clinical trials in renal cancer in the US (IV)
23 February 2004 Data presented at the JP Morgan 22nd Annual Healthcare Conference held in January 2004 have been added to the
cancer therapeutic trials section[47]
9 September 2003 Phase II clinical trials in breast cancer in the US (IV)
13 June 2003 Phase I/II clinical trials in HIV infections treatment in the US (IV)
31 May 2003 Cell Genesys and Medarex have entered into an agreement to develop a combination therapy using GVAX and
ipilimumab
30 September 2002 Phase II clinical trials in lymphoma in the US (IV)
8 November 2001 A phase I/II study has been added to the cancer therapeutic trials section[51]
8 November 2001 Phase II clinical trials for malignant melanoma in the US (IV)
8 November 2001 Phase II clinical trials for prostate cancer in the US (IV)
18 January 2000 Anti-CTLA-4 monoclonal antibodies are available for licensing from Medarex (http://www.medarex.com)
1 December 1999 A preclinical study has been added to the pharmacodynamics section
3 November 1998 A preclinical study has been added to the pharmacodynamics section
16 May 1996 New profile
16 May 1996 Preclinical development for cancer in the US (IV)
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in a phase II trial in 44 patients with hormone
refractory prostate cancer. Four patients experi-
enced an immune breakthrough event, with the
most common events being diarrhea, colitis, and
adrenal or pituitary insufficiency.[31]
Phase I : Results from a phase I clinical trial in
18 patients with hormone refractory prostate
cancer showed that ipilimumab (0.5–3.0mg/kg)
in combination with subcutaneous sargramostim
(250mg/m2/day) was generally well tolerated.
The two patients who responded to treatment
both experienced an immune breakthrough event
(recognized AE), one of rash and one of hypo-
pituitarism.[31,32]
Combination therapy with ipilimumab and
GVAX did not result in any dose-limiting toxicities
in 12 patients with metastatic hormone-refractory
prostate cancer. In the five patients who experienced
a prostate specific antigen (PSA) response, all ex-
perienced grade 2/3 immune-mediated endocrine
deficiencies, which were successfully treated with
standard hormone replacement. Importantly, the
PSA declines could not be consistently correlated
with declines in adrenal androgens and there
was no induction of the alpha-21-hydroxylase
auto-antibody that is seen in 90% of cases of
auto-immune adrenal insufficiency. Two patients
requiring thyroid replacement therapy were suc-
cessfully tapered off after recovery of thyroid
function, with one patient subsequently main-
taining a PSA response. One patient who received
the highest dose of ipilimumab tested in the trial
developed a grade 3 dose-limiting pulmonary al-
veolitis that responded to steroid treatment.[19,33]
Preliminary data from a phase I study of
ipilimumab alone and in combination with radio-
therapy in patients with metastatic castration-
resistant prostate cancer showed irAEs. Nineteen
patients experienced 29 irAEs, including diarrhea/
colitis (14), rash (9), hepatitis (4), and endo-
crinopathy (2). Nine patients had grade ‡3 irAEs,
including gastrointestinal (6), hepatitis (2), and




In a phase II trial involving 115 patients with
advanced melanoma, an overall mean increase of
approximately 10% in activated CD4+ and CD8+
T cells, and a decrease in naive CD4+ and CD8+
T cells was observed by week 4. By week 4, 96% of
evaluable patients had an increase in activated T
cells and 82% of evaluable patients had a decrease
in naive T cells. In more than 50% of patients,
these changes continued to evolve between weeks
4 and 12.[35]
Combination therapy with GVAX and ipili-
mumab in a phase I trial of patients with meta-
Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Lymphoma NE 30% (NYR) 21 Jul 2009
Malignant melanoma 5 Jan 2013 51% (C) 9 Jun 2010
Non-small cell lung cancer NE 30% (NYR) 21 Jul 2009
Prostate cancer NE 30% (NYR) 21 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘‘A’’ indicating significantly above average/likely to progress, ‘‘C’’ indicating
average, and ‘‘F’’ indicating significantly below average/unlikely to progress. ‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability
of approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate; NYR = not yet rated.
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static hormone-refractory prostate cancer, enhanced
T cell and dendritic cell activity, and this was more
pronounced at the higher dose levels. Evaluation
of antibody responses showed that the combina-
tion therapy induced antibody responses to a broad
array of previously identified cancer-associated anti-
gens including PSMA, NY-ESO-1, and filamin-B,
and that these responses were patient-specific with




Preliminary results from a phase I trial in
which patients withmetastatic, hormone-refractory
prostate cancer were treated with subcutaneous
GM-CSF (250mg/m2/day) and escalating doses
of ipilimumab showed that two of three patients
treated with ipilimumab (3.0mg/kg) in combi-
nation with sargramostim experienced >50% de-
creases in PSA serum levels. Seven patients out of
a total of 18 evaluable patients had a <50% re-
duction in their PSA levels. A dose-response rela-
tionship was seen between the ipilimumab dose and
CD8 T-cell activation. Interferon-g produc-
tion and lytic activity were enhanced in antigen-
specific CD8+ T cells following treatment.[31,32]
Decreases in serum PSA levels of >50% were
seen in 3 of 24 hormone-refractory prostate can-
cer patients treated with ipilimumab in a phase II
trial. Ipilimumab in combination with docetaxel
resulted in decreases in serum PSA levels of >50%
in 3 of 20 patients.[31]
Twelve patients with advanced prostate cancer
have completed treatment in an ongoing phase I
combination trial of GVAX and ipilimumab.
An association was observed between the dose-
dependent increase in T-cell activation and decreases
in PSA levels. According to this trial, patients
receiving the three highest doses of ipilimumab in
combinationwithGVAX immunotherapy showed
an increase in the percentage of memory T cells,
asmeasured through peripheral blood T-cell mon-
itoring. Patients receiving the two highest doses
of ipilimumab in combination with GVAX
immunotherapy had an increase in HLA-DR on




Phase III : Overall survival was significantly
extended in patients with previously-treated
metastatic melanoma who received ipilimumab
therapy in a phase III trial (study 020,
NCT00094653) of the agent alone and in combi-
nation with a gp100 peptide vaccine. In this
double-blind trial, patients were randomized to
receive ipilimumab plus gp100 (3mg/kg and
1mg/kg every 3 weeks for four doses; n= 403),
ipilimumab plus placebo (3mg/kg every 3 weeks
for four doses; n= 137) or gp100 plus placebo
(n = 136). Re-induction was allowed within 28
days of documented progression, provided the
patient had no experienced any dose-limiting
toxicities or response to the initial cycle of ther-
apy was stable disease lasting ‡3 months from the
first tumor assessment at week 12, or complete or
partial response. Patients were re-induced with
1–3 additional courses of the originally assigned
regimen in 7.2%, 6.5%, and 1% of ipilimumab
plus gp100, ipilimumab and gp100 arms, respect-
ively. Median overall survival was 10, 10.1, and
6.4 months for patients treated with ipilimumab
plus gp100, ipilimumab alone and gp100 alone,
respectively (hazard ratio [HR] 0.68 and 0.66,
p= 0.0004 and 0.0026; for the comparisons between
the ipilimumab plus gp100 and gp100 groups, and
ipilimumab and gp100 groups, respectively). At
1 year, 44–46% of patients treated with ipilimumab
were alive compared with 25% of patients treated
with gp100 alone. At 2 years, 22–24% of patients
treated with ipilimumab were alive compared
with 14% of patients treated with gp100 alone.[5,6]
Phase II : Two-year survival rates in three
phase II trials of ipilimumab 10mg/kg in patients
with advanced metastatic melanoma (stage III or
IV) were 33%, 30%, and 41% (for trials 008, 022,
and 007, respectively) based on follow-up of up to
37.5 months. One-year survival rates reported
previously in the three studies were 47%, 48%,
and 51%, respectively, based on median follow-
up periods of 24.8 months, 21.88 months, and
26.32 months, respectively. Study 008 included
155 patients who had progressed while on, or
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after, receiving standard treatment. Study 022
included 217 patients who were previously treat-
ed, relapsed or failed to respond to experimental
treatment, or were unable to tolerate currently
approved therapies. Study 007 included 115
treatment-naive patients and patients previously
treated with therapy other than ipilimumab.[22,37]
A 2-year projected survival rate of 30% and a
median overall survival of 13.4months was seen in
heavily pre-treated melanoma patients in a phase
I/II study (MDX010-15) in 23 patients. The me-
dian follow-up for survival was 15.5 months.[38,39]
There was no significant difference between
ipilimumab plus budesonide and ipilimumab plus
placebo in the disease control rate (31% vs 35%)
or in the best overall clinical response rate (12%
vs 16%) in a phase II trial in patients with ma-
lignant melanoma. 115 patients with unresect-
able stage III or IV malignant melanoma (who
were either treatment naive or had received pre-
vious treatment with systemic therapy for ad-
vanced melanoma) were treated with ipilimumab
10mg/kg/day every 3 weeks for four courses, plus
placebo or budesonide at a dosage of 9mg/day to
week 12, 6mg/day to week 14, and 3mg/day to
week 16. Eligible patients could enter mainten-
ance treatment with ipilimumab 10mg/kg/day
every 12 weeks, at week 24. The modified WHO
best overall response rate (primary endpoint) was
5.8%. Late responses or stable disease with a
decline in tumor volume of more than 25% were
also observed. Median follow-up for survival was
9.5 months, with a median overall survival of
10.22 months. Based on the initial survival anal-
ysis at 6 months in 12 patients with brain meta-
stases, one patient survived less than 6 months,
and three survived between 6 and 9 months. The
remaining eight patients were alive at 2.56+,
5.32+, 6.05+, 6.11+, 6.74+, 8.51+, 10.81+, and
14.06+months. One patient experienced a partial
response, and three experienced stable disease. In
the only patient with a brain lesion as an index
lesion, the lesion decreased by week 12. The survival
rate at 1 year was 46.67%. There was a significant
dose effect based on best overall response with
highest activity in the 10mg/kg group.[23,25,26,40,41]
In a follow-up study to determine overall sur-
vival in patients with metastatic melanoma pre-
viously enrolled in three phase I and II studies
performed between 2000 and 2005, the median
overall survival for responders had not been
reached with a 25th percentile of 21.7 months.
The median overall survival for patients in Med-
arex studies -02, -08, and -015 were 19.4, 12.9,
and 10.0 months, respectively. In contrast, the
median overall survival for non-responders was
10.9 months, with 25th and 75th percentile over-
all survival of 5.7 and 19.4 months.[42]
In a phase II study of previously treated
patients with unresectable stage III/IV melano-
ma, an Independent Review Committee con-
cluded that the best overall response rates were
similar when ipilimumab was used either as a first
or second-line monotherapy.[43]
Long-term follow-up data and overall survival
results from the phase II study, MDX010-08, of
ipilimumab in combination with dacarbazine
demonstrated that 11.4% (4 of 35 patients) were
alive at ‡4 years of follow-up. The median overall
survival time for patients treated with the com-
bination therapy was 15 months compared with
the median overall survival data from the liter-
ature of 6–9 months for patients with advanced
melanoma receiving standard chemotherapy.[44]
Overall disease control was achieved in 19% of
patients in a phase II dose-escalation trial of ipi-
limumab in patients with unresectable stage III or
stage IV malignant melanoma. The study en-
rolled 88 patients in three cohorts. In the cohort
of 23 patients who were treated at 10mg/kg,
disease control was achieved in 39% (9 of 23),
which lasted 6 months or longer in nearly
all patients (8 of 9). Duration of disease stabili-
zation or response exceeded 6 months in 15%
(13 of 88) of patients. The longest effect ob-
served (stable disease) is ongoing for more than
1 year.[45]
Results from the initial cohort of this phase II
study showed an objective response rate of 21%
which included two complete responses and one
partial response. There also appeared to be an
apparent correlation between the development of
an autoimmunity and durable clinical responses.
Six patients reported drug-related autoimmune
adverse events, which were resolvable with med-
ication, and of these, 50% also experienced an
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anti-tumor response. The results suggest that
these ‘autoimmune break through events’ may be
associated with the induction of anticancer im-
mune responses. Patients received a regimen of
3.0mg/kg of MDX 010 once every 3 weeks in
combination with two peptides from the gp100
melanoma-associated antigen gp100.[46]
In preliminary results from a phase II study of
30 melanoma patients treated with MDX 010 in
combination with dacarbazine, there were two
partial responses, three unconfirmed partial re-
sponses and five reports of stable disease com-
pared to one partial response and four stable
disease reports in patients receiving dacarbazine
monotherapy.[47]
In a phase II study, MDX 010 in combination
with MDX 1379 at doses of 3 or 1mg/kg/day was
associated with complete responses in 7% and
0%, respectively, and partial responses in 7% and
11%, respectively, of 56 patients with metastatic
malignant melanoma. The complete response
duration was >30 and >31 months, while the
partial response duration was 4 to >34 months.[27]
Interim results from 12 months’ extended dos-
ing with ipilimumab (3.0mg/kg) andMDX 1379 in
25 patients with resected stage IIIc or stage IV
melanoma showed that six patients had relapsed
but all 25 were still alive at the time of follow-up.[28]
In results from a phase I/II trial in 36 meta-
static melanoma patients receiving MDX 010 in
combination with IL-2, eight patients experienced
objective tumor regression. Patients received
MDX 010 every 3 weeks, with three patients
per dose level at 0.1, 0.3, 1.0, and 2.0mg/kg.
Two patients in the 3.0mg/kg cohort experi-
enced complete responses that are ongoing at
over 13 months, and one patient in the 2.0mg/kg
cohort experienced a complete response that was
ongoing at over 16 months. Five patients experi-
enced partial responses, with responses ranging
from 7 months to the longest duration ongoing at
over 19 months.[29]
Non-Small Cell Lung Cancer
Phase II : In a double-blind, phase II trial (041)
in patients with previously untreated advanced
non-small cell lung cancer, treatment with ipili-
mumab in combinationwith paclitaxel/carboplatin
resulted in immune-related progression-free sur-
vival rate of 5.52 months (p = 0.094), 5.68 months
(p = 0.026) and 4.63 months for the concurrent,
phased and paclitaxel/carboplatin alone groups,
respectively. Progression-free survival, as assess-
ed by modified WHO criteria, was 4.11 months
(p = 0.250), 5.13 months (p = 0.024) and 4.21
months for the concurrent, phases and paclitaxel/
carboplatin alone groups, respectively. Interim
data for overall survival were 11.01 months,
11.56 months, and 9.99 months for the con-
current, phased and paclitaxel/carboplatin alone
groups, respectively.[16]
Prostate Cancer
Phase II : A confirmed response of 246 days in
duration and a confirmed response of ‡79 days in
duration were seen in 2 of 24 hormone refractory
prostate cancer patients treated with ipilimumab
in a phase II trial. There was also a third uncon-
firmed response. Ipilimumab in combination
with docetaxel resulted in one confirmed response
(280 days) and two unconfirmed responses.[31]
Phase I : Twelve patients with advanced pros-
tate cancer have completed treatment in an on-
going phase I combination trial of GVAX and
ipilimumab. Of the six patients treated in the two
highest dose groups, antitumor activity has been
observed in five patients. PSA declines of greater
than 50% were maintained in four of these
patients for at least 6 months, with the longest
response ongoing at more than 16 months. Clin-
ical evidence of antitumor activity has been ob-
served in four of five PSA responders, including
complete resolution of multiple lesions on bone
scan in two patients, and resolution of abdominal
lymph node disease by CT scan and improvement
in bone pain in one patient each. Additional data
showed that in the 16 patients from the expansion
cohort, an ipilimumab dose-related association
with increased T-cell activation was seen. Asso-
ciated anti-tumor activity was seen from the ini-
tial 12 patients.[17,19,33,48]
Preliminary data from an ongoing phase I
study of ipilimumab in combination with sargra
mostim showed that of the six patients treated at
3mg/kg ipilimumab, three patients experienced
decreases in prostate-specific antigen serum
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levels of over 50% and one patient experienced a
partial response in hepatic metastases.[17,49]
Lymphoma
Phase I : Preliminary results from a phase I/II
clinical trial in patients with relapsed or refrac-
tory follicular lymphoma showed that one of six
patients who had been previously treated with a
lymphoma vaccine experienced a partial response
that was ongoing at >10 months duration.[20]
Renal Cancer
Phase I : MDX 010 had moderate efficacy in a
phase II study in patients with metastatic renal
cancer. Partial clinical response rates were 5%
and 13% for patients in the 1 and 3mg/kg/day
treatment groups, respectively. Significantly
more patients who experienced a major immune-
mediated event achieved an objective clinical
response compared with those who did not.[50]
Solid Tumors
Phase I: Treatment with a single dose of ipili-
mumab 3mg/kg via infusion resulted in stable
disease and marked reduction in CA 125 (from
3478 to 145) with tumor regression in two ovarian
cancer patients, respectively. The patients had
previously received treatment with GVAX and
are part of a phase I trial, which will accrue
48 patients with a range of solid tumors. Results
from a pilot study, in which all patients had pre-
viously received treatment with GVAX, also
showed a reduction in CA 125 levels following
treatment with ipilimumab in two ovarian cancer
patients. In addition, ipilimumab induced ex-
tensive tumor destruction with lymphocyte and
granulocyte infiltrates in all three melanoma
patients in the pilot study.[21]
Among 18 patients with metastatic melanoma
and 14 patients with hormone-refractory prostate
cancer receiving a single dose of ipilimumab
3mg/kg, two prostate cancer patients experienced
a >50% reduction in serum PSA levels that lasted
for 3–6 months.[51]
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